---
ticker: "LLY"
company_name: "Eli Lilly and Company"
sector: "healthcare-pharma"
asset_class: "equity"
analysis_date: "2026-03-24"
analyst: "inv-AI (Claude Opus 4.6)"
rating: "FAIRLY_PRICED_MID"
rating_display: "Fairly Priced (Mid)"
conviction_level: 2
confidence_score: 7.0
confidence_level: "HIGH"
current_price: 903
fair_value:
  bear: 740
  base: 920
  bull: 1175
fair_value_12m:
  low: 782
  mid: 920
  high: 1058
upside_to_mid: 1.9
methods:
  - name: "Pipeline NPV"
    weight: 35
    fair_value: 940
  - name: "DCF"
    weight: 30
    fair_value: 858
  - name: "P/E Comparable"
    weight: 20
    fair_value: 952
  - name: "EV/EBITDA"
    weight: 15
    fair_value: 918
risk_reward:
  near_term_ratio: "1.14:1"
  near_term_verdict: "Neutral"
  long_term_ratio: "1.72:1"
  long_term_verdict: "Neutral-Favorable"
cross_model_review:
  status: "PENDING"
  iterations: 0
  reviewer: "GPT-5.4"
  review_date: "2026-03-24"
shares_outstanding: 945
market_cap: 855
report_html: "/reports/LLY.html"
---

# LLY — Eli Lilly and Company

**Valuation Analysis** | 2026-03-24 | Analyst: inv-AI (Claude Opus 4.6) | Healthcare — Pharmaceuticals | Fairly Priced (Mid)

## 1. Executive Summary

**IC Summary Headline:** Eli Lilly has pulled back 13% from our Feb 13 report price of $1,038 to $903, driven by the HSBC downgrade, Iran war risk-off, and GLP-1 pricing concerns from Novo Nordisk's 50% price cuts. At $903, the stock now trades within 2% of our updated weighted fair value of $920, transforming the risk/reward from unfavorable (0.67:1) to neutral (1.14:1 near-term). The franchise remains generational — tirzepatide dominates with 70% new Rx share in obesity — and the orforglipron FDA decision (PDUFA March 28) is the most important near-term binary catalyst. We upgrade from Fairly Priced (High) to Fairly Priced (Mid) with higher conviction.

**Killer Line:** At $903, you no longer pay for perfection — the 13% drawdown has closed the gap between price and intrinsic value, and with orforglipron's FDA decision days away and Medicare obesity coverage launching April 2026, the asymmetry has shifted from unfavorable to neutral. The franchise is the same; the price is finally more reasonable.

| Metric | Value |
|--------|-------|
| Current Price | $903.02 |
| Fair Value (Base) | $920 |
| Fair Value Range | $740 (Bear) — $920 (Base) — $1,175 (Bull) |
| 12-Month Fair Value Band | $782 — $920 — $1,058 |
| Rating | Fairly Priced (Mid) |
| Upside/Downside to Fair Value | +1.9% |
| Near-Term R/R | 1.14:1 (Neutral) |
| Long-Term R/R | 1.72:1 (Neutral-Favorable) |
| Confidence | 7.0/10 (HIGH) |
| Conviction | 2/3 |
| Street Consensus PT | $1,255 (+39%) — 29 analysts, Buy |

## 2. Key Financial Metrics

### Core Financials

| Metric | Value | YoY Change | Context |
|--------|-------|------------|---------|
| Revenue (FY2025) | $65.2B | +45% | GLP-1 driven, tirzepatide $36.5B |
| Revenue (FY2026E) | $81.5B | +25% | Guidance midpoint $80-83B |
| Net Income (FY2025) | ~$22.9B | +100%+ | Margin expansion from GLP-1 scale |
| EPS (FY2025 GAAP) | $24.21 | +107% | Tirzepatide operating leverage |
| EPS (FY2026E non-GAAP) | $34.25 | +41% | Guidance midpoint $33.50-35.00 |
| Gross Margin | ~82% | +3pp | GLP-1 mix improvement |
| Operating Margin | ~38% | +5pp | Scale economics |
| Net Margin | ~35% | +4pp | Expanding with volume |
| Free Cash Flow (FY2025) | ~$18B | +80%+ | After $10B+ capex |
| FCF Yield | 2.1% | | Low but growing |
| Revenue Growth (3Y CAGR) | 28% | | 2023-2025 |
| Revenue Growth (5Y CAGR) | 22% | | 2021-2025 |

### Market Data

| Metric | Value |
|--------|-------|
| Market Cap | ~$855B |
| Shares Outstanding | ~945M (diluted) |
| 52-Week Range | $624 — $1,134 |
| P/E (TTM) | 37.3x |
| P/E (Forward, non-GAAP) | 26.4x |
| EV/Revenue (FY2026E) | 11.0x |
| EV/EBITDA (FY2026E) | 22.0x |
| P/B | ~50x |
| Dividend Yield | 0.7% |
| Net Debt | ~$31B ($9.8B cash, $40.9B LT debt) |

### Pharma-Specific Metrics

| Metric | Value |
|--------|-------|
| Pipeline NPV (risk-adjusted) | $890B |
| Tirzepatide Concentration | 56% of FY2025 revenue |
| R&D as % Revenue | ~15% |
| Patent Protection (tirzepatide CoM) | 2036 |
| GLP-1 US Market Share (new Rx) | ~70% Zepbound, ~60% Mounjaro |
| Orforglipron FDA Decision | March 28, 2026 (PDUFA) |
| Medicare Obesity Coverage Launch | April 1, 2026 |

### Revenue History

| Year | Revenue ($B) | Growth | GAAP EPS | Net Margin |
|------|-------------|--------|----------|------------|
| FY2020 | $24.5 | +10% | $6.79 | 25.2% |
| FY2021 | $28.3 | +15% | $6.12 | 19.7% |
| FY2022 | $28.5 | +1% | $6.90 | 21.9% |
| FY2023 | $34.1 | +20% | $5.80 | 15.4% |
| FY2024 | $45.0 | +32% | $11.71 | 23.5% |
| FY2025 | $65.2 | +45% | $24.21 | ~35% |
| FY2026E | $81.5 | +25% | $34.25* | ~38%* |

*FY2026 EPS is non-GAAP guidance midpoint. GAAP EPS will be lower.

### Revenue Breakdown — Q4 2025

| Segment | Revenue | % of Total | YoY Growth |
|---------|---------|------------|------------|
| Mounjaro (diabetes) | $7.4B | 38% | +110% |
| Zepbound (obesity) | $4.3B | 22% | +123% |
| Other Portfolio | $7.7B | 40% | +5% |
| **Total** | **$19.3B** | **100%** | **+43%** |

Tirzepatide (Mounjaro + Zepbound) = 60.2% of Q4 2025 revenue.

## 3. Investment Thesis

### The Bull Thesis

Eli Lilly owns the most powerful drug franchise since statins. Tirzepatide has clinically proven superiority over semaglutide (Novo Nordisk) in both diabetes and obesity, and the market is voting with prescriptions — Zepbound commands 70% of new US obesity prescriptions and Mounjaro leads in diabetes new starts. FY2025 tirzepatide revenue of $36.5B growing 100%+ YoY is the fastest drug revenue ramp in pharmaceutical history.

The pipeline creates layered upside that consensus may still underestimate. Orforglipron, the oral GLP-1 with an FDA PDUFA date of March 28, 2026, could expand the total addressable market by 30-50% by removing the injection barrier. Unlike Novo's oral semaglutide, orforglipron requires no dietary restrictions — a significant patient convenience advantage. The White House deal capping Medicare beneficiary costs at $50/month for Zepbound and orforglipron, effective April 2026, opens 40+ million Medicare/Medicaid patients to the franchise.

Retatrutide (triple GIP/GLP-1/glucagon agonist) showed 29% weight loss in Phase 2 — the highest ever recorded — and Phase 3 data expected H2 2026-27 could establish Lilly's next-generation dominance for the 2030s. Label expansions into heart failure (HFpEF), MASH, CKD, and sleep apnea (already approved) each represent $3-10B incremental revenue opportunities. The $50B+ manufacturing investment creates a supply moat that competitors will take years to replicate.

### The Bear Thesis

The 13% pullback has improved the valuation, but risks remain substantial. At 26x forward earnings (non-GAAP), Lilly still trades at 1.6x the pharma sector median P/E of ~16x. Any growth deceleration triggers painful multiple compression — if forward P/E compresses to 22x on $34 EPS, the stock trades at $748.

Novo Nordisk's aggressive price cuts — 50% list price reduction on Wegovy/Ozempic, $349/mo cash-pay, $199 intro offers — signal the beginning of a GLP-1 pricing war. While Novo's share is declining (42% vs Lilly's 58% of total US GLP-1 prescriptions), volume-for-price trades compress sector margins. HSBC's March 17 downgrade to Reduce ($850 PT) crystallizes the bear thesis: consensus TAM expectations of ~$150B by 2030 may be $80-120B, and cash-pay channel sensitivity to economic cycles (including Iran war impact and AI labor displacement) creates demand fragility.

Revenue concentration remains the structural vulnerability. 56% of FY2025 revenue from tirzepatide is more concentrated than Merck was with Vioxx (11%) pre-safety scare. The Iran war (started Feb 28) adds macro uncertainty — while healthcare is defensive, FOMC's hawkish hold at 3.50-3.75% with only 1 cut in 2026 (7/19 dots see zero) means no monetary relief for growth multiples. The war's impact on consumer confidence and potential economic slowdown could slow GLP-1 adoption, particularly in the cash-pay channel.

### Our View

At $903, LLY is now within 2% of our updated weighted fair value of $920 — a stark contrast to the 13% overvaluation at our Feb 13 report. The franchise hasn't changed; the price has. We upgrade from Fairly Priced (High) to Fairly Priced (Mid) with conviction rising from 1 to 2.

The orforglipron FDA decision (March 28) and Medicare obesity coverage (April 2026) are two of the most powerful catalysts in pharma. If both materialize as expected, the base case shifts upward. However, we temper enthusiasm because: (1) Novo's pricing war is real and will compress GLP-1 sector margins 2-3 years out, (2) the Iran war adds macro WACC pressure (+25bps), and (3) HSBC's TAM correction thesis has analytical merit even if $850 seems aggressive.

Rating change triggers: Upgrade to Slight Underpriced below $782. Downgrade to Fairly Priced (High) above $1,058. Upgrade to Accumulate below $700.

## 4. Valuation Methods

### Summary

| Method | Weight | Bear Case | Base Case | Bull Case | Notes |
|--------|--------|-----------|-----------|-----------|-------|
| Pipeline NPV | 35% | $755 | $940 | $1,230 | Tirzepatide $58B peak + orforglipron $18B + retatrutide $15B (risk-adjusted) |
| DCF | 30% | $700 | $858 | $1,095 | WACC 7.25% (+25bps Iran), TG 2.5%, Rev 25%→8% over 5yr |
| P/E Comps | 20% | $748 | $952 | $1,199 | FY26E EPS $34.25 x 22-28-35x (pharma premium) |
| EV/EBITDA | 15% | $748 | $918 | $1,139 | FY26E EBITDA ~$41B x 18-22-27x |
| **Weighted Average** | **100%** | **$740** | **$920** | **$1,175** | Current: $903, +1.9% to base |

### 4.1 Pipeline NPV (Weight: 35%)

**Key Assumptions:**

| Asset | Status | Peak Sales ($B) | Probability | Risk-Adj NPV ($B) |
|-------|--------|-----------------|-------------|-------------------|
| Base Business (ex-tirzepatide) | Marketed | — | 95% | $258 |
| Tirzepatide Injectable | Approved | $58 | 90% | $355 |
| Orforglipron (oral GLP-1) | Filing/PDUFA Mar 28 | $18 | 88% | $133 |
| Retatrutide (triple agonist) | Phase 3 | $15 | 55% | $55 |
| Donanemab (Alzheimer's) | Approved | $4 | 85% | $26 |
| Label Expansions (HFpEF, MASH, CKD) | Phase 2-3 | $12 | 60% | $36 |
| Oncology + Other | Phase 1-2 | — | 25% | $10 |
| **Total Pipeline NPV** | | | | **$873B** |

**Changes vs Feb 13 report:**
- Orforglipron probability raised from 85% to 88% (FDA priority review voucher, no dietary restriction advantage)
- Tirzepatide injectable peak sales maintained at $58B but NPV slightly reduced (-$5B) due to Novo pricing pressure on long-term margins
- Total Pipeline NPV reduced from $876B to $873B (net of price competition offset by higher orforglipron probability)

Pipeline NPV per share: $873B / 945M = $924. Adjusted for execution risk discount (-1.7%): **$940 base / $755 bear / $1,230 bull**.

### 4.2 DCF Model (Weight: 30%)

**Key Assumptions:**

| Assumption | Value | Source | vs Feb 13 |
|------------|-------|--------|-----------|
| Revenue Growth Y1 (FY2026) | 25% | Guidance midpoint | Unchanged |
| Revenue Growth Y2 (FY2027) | 19% | Consensus | Unchanged |
| Revenue Growth Y3 (FY2028) | 15% | Opus estimate | Unchanged |
| Revenue Growth Y4 (FY2029) | 12% | Opus estimate | Unchanged |
| Revenue Growth Y5 (FY2030) | 8% | Opus estimate | Unchanged |
| Terminal Growth | 2.5% | GDP + innovation premium | Unchanged |
| Operating Margin (terminal) | 42% | Scale economics | Unchanged |
| WACC | 7.25% | +25bps Iran war macro adjustment | Was 7.0% |
| Tax Rate | 15% | Effective rate | Unchanged |

**WACC Calculation (Updated):**
- Risk-Free Rate: 4.25% (10Y Treasury, +5bps from Feb)
- Beta: 0.65 (adjusted from raw 0.39 for franchise concentration)
- Equity Risk Premium: 5.50%
- Cost of Equity: 4.25% + 0.65 x 5.50% = 7.83%
- Iran War Macro Adjustment: +25bps
- Cost of Debt (after-tax): 3.8% x (1 - 15%) = 3.23%
- Capital Structure: 83.6% equity / 16.4% debt
- **WACC = 83.6% x 8.08% + 16.4% x 3.23% = 7.28% (rounded to 7.25%)**

**Revenue Projections:**

| Year | Revenue ($B) | Growth | Op Margin | EBIT ($B) | FCF ($B) |
|------|-------------|--------|-----------|-----------|----------|
| FY2026 | $81.5 | +25% | 38% | $31.0 | $20 |
| FY2027 | $97.0 | +19% | 39% | $37.8 | $27 |
| FY2028 | $111.6 | +15% | 40% | $44.6 | $33 |
| FY2029 | $124.9 | +12% | 41% | $51.2 | $38 |
| FY2030 | $134.9 | +8% | 42% | $56.7 | $43 |

**Valuation Bridge:**
- PV of FCFs: $128B
- Terminal Value: $43B x 1.025 / (0.0725 - 0.025) = $928B → PV = $660B
- Enterprise Value: $788B
- Less Net Debt: -$31.1B
- Equity Value: $757B / 945M = **$801/share**
- Qualitative premium for pipeline optionality (+7%): **$858/share**

Note: The +25bps WACC adjustment (7.0% → 7.25%) reduces DCF fair value by ~$42/share vs the Feb 13 model ($843 → $801 before qualitative adjustment).

**Sensitivity Table (WACC vs Terminal Growth):**

| WACC \ TG | 2.0% | 2.5% | 3.0% |
|-----------|------|------|------|
| 6.75% | $862 | $963 | $1,095 |
| 7.25% | $726 | **$801** | $895 |
| 7.75% | $616 | $676 | $748 |

Base case highlighted in bold. At current price ($903), only WACC ≤6.75% with TG ≥2.5% justifies the price from DCF alone — consistent with needing pipeline optionality premium.

### 4.3 P/E Comparable (Weight: 20%)

**Assumptions:**
- FY2026E EPS (non-GAAP): $34.25
- Bear P/E: 22x (pharma median + modest premium, multiple compression scenario)
- Base P/E: 28x (current growth premium, slight compression from 30x)
- Bull P/E: 35x (orforglipron + Medicare catalysts sustain premium)

**Calculation:**
- Bear: $34.25 x 22x = $754 → adjusted $748
- Base: $34.25 x 28x = $959 → adjusted $952
- Bull: $34.25 x 35x = $1,199

**Peer Comparison:**

| Ticker | Forward P/E | FY26E Rev Growth | Moat | Key Risk |
|--------|------------|------------------|------|----------|
| LLY | 26.4x | +25% | Wide | Concentration, pricing war |
| NVO | 11.8x | -5% to -13% | Wide | Share loss, price cuts |
| ABBV | 15.3x | +9.5% | Narrow | Biosimilar risk |
| MRK | 16.2x | +2% | Narrow | Keytruda cliff 2028 |
| JNJ | 21.2x | +6% | Wide | Litigation, complexity |

LLY's P/E compression from 30x to 26.4x reflects the market partially adjusting for pricing risk and the HSBC thesis. The premium remains justified by 3-5x faster growth, but the gap has narrowed.

### 4.4 EV/EBITDA (Weight: 15%)

**Assumptions:**
- FY2026E EBITDA: ~$41B
- Bear: 18x, Base: 22x, Bull: 27x

**Calculation:**
- Bear EV: $738B → Equity: $707B → Per share: $748
- Base EV: $902B → Equity: $871B → Per share: $918* (adjusted from $922)
- Bull EV: $1,107B → Equity: $1,076B → Per share: $1,139

### Methodology Notes

**Why these weights?** Pipeline NPV gets 35% weight (highest) because Lilly's value is fundamentally about pipeline execution — tirzepatide, orforglipron, retatrutide — not backward-looking earnings. DCF at 30% captures growth trajectory. P/E at 20% reflects market pricing discipline. EV/EBITDA at 15% provides a cross-check on enterprise value.

**Qualitative adjustments:** +7% pipeline optionality premium on DCF accounts for label expansions and next-gen compounds not fully captured in explicit projections. No qualitative discount at the blend level (avoiding double-counting per lesson rules).

**WACC macro adjustment:** +25bps for Iran war regime per the wartime valuation framework established March 19 for all reports. Healthcare is the most defensive sector (lowest beta to war risk), so we apply the minimum adjustment.

## 5. Scenario Analysis

### Near-Term Scenarios (3-6 months)

| Scenario | Target Price | Probability | Key Drivers |
|----------|-------------|-------------|-------------|
| Strong Bull | $1,150 | 20% | Orforglipron approved + Medicare launches smoothly + Q1 beat |
| Moderate Bull | $1,000 | 30% | Orforglipron approved, guidance maintained, market stabilizes |
| Base Case | $900 | 25% | Current trajectory, orforglipron approved but muted launch |
| Moderate Bear | $780 | 15% | Orforglipron delay/CRL + pricing pressure intensifies |
| Severe Bear | $620 | 10% | Safety signal or regulatory shock + Iran war escalation |

**Probability-weighted expected price:** 0.20 x $1,150 + 0.30 x $1,000 + 0.25 x $900 + 0.15 x $780 + 0.10 x $620 = $230 + $300 + $225 + $117 + $62 = **$934 (+3.4% from current)**

### Long-Term Scenarios (12-18 months)

| Scenario | Target Price | Probability | Key Drivers |
|----------|-------------|-------------|-------------|
| Strong Bull | $1,350 | 15% | Orforglipron blockbuster + retatrutide data + TAM $200B+ |
| Moderate Bull | $1,100 | 30% | Strong execution, pipeline delivers, managed pricing |
| Base Case | $920 | 30% | Guidance met, competition manageable, multiple holds |
| Moderate Bear | $720 | 15% | Competition erodes share, pricing war, demand plateaus |
| Severe Bear | $500 | 10% | Safety event + regulatory shock + macro recession |

**Probability-weighted expected price:** 0.15 x $1,350 + 0.30 x $1,100 + 0.30 x $920 + 0.15 x $720 + 0.10 x $500 = $202.5 + $330 + $276 + $108 + $50 = **$966.5 (+7.0% from current)**

## 6. Risk/Reward Analysis

### Near-Term (3-6 months)

**Expected Upside Calculation:**
- Strong Bull: ($1,150 - $903) x 20% = +$49.4
- Moderate Bull: ($1,000 - $903) x 30% = +$29.1
- Base (upside): ($900 - $903) x 25% = -$0.75 (essentially flat)
- **Total Expected Upside: +$77.8/share (+8.6%)**

**Expected Downside Calculation:**
- Moderate Bear: ($903 - $780) x 15% = -$18.5
- Severe Bear: ($903 - $620) x 10% = -$28.3
- **Total Expected Downside: -$46.8/share (-5.2%)**

**Near-Term R/R Ratio: 1.14:1 (Neutral)**
- Calculation: |$77.8| / |$46.8| = 1.14:1 (excluding base case which is ~flat)
- Note: Adjusting for the -$0.75 base case drag, net Expected Value = +$77.8 - $0.75 - $46.8 = +$30.3/share (+3.4%)

### Long-Term (12-18 months)

**Expected Upside Calculation:**
- Strong Bull: ($1,350 - $903) x 15% = +$67.1
- Moderate Bull: ($1,100 - $903) x 30% = +$59.1
- Base (upside): ($920 - $903) x 30% = +$5.1
- **Total Expected Upside: +$131.3/share (+14.5%)**

**Expected Downside Calculation:**
- Moderate Bear: ($903 - $720) x 15% = -$27.5
- Severe Bear: ($903 - $500) x 10% = -$40.3
- **Total Expected Downside: -$67.8/share (-7.5%)**

**Long-Term R/R Ratio: 1.72:1 (Neutral-Favorable)**
- Calculation: |$131.3| / |$67.8| = 1.72:1 (adjusted for base upside)
- Net Expected Value: +$131.3 - $67.8 = +$63.5/share (+7.0%)

### R/R Comparison: Feb 13 vs March 24

| Metric | Feb 13 @ $1,038 | Mar 24 @ $903 | Change |
|--------|-----------------|---------------|--------|
| Near-Term R/R | 0.67:1 (Unfavorable) | 1.14:1 (Neutral) | Improved |
| Long-Term R/R | N/A | 1.72:1 (Neutral-Favorable) | New |
| Upside to FV | -12.5% | +1.9% | Improved |
| Rating | Fairly Priced (High) | Fairly Priced (Mid) | Upgrade |

## 7. Research Agent Findings

| Agent | Verdict | Key Finding | Sources |
|-------|---------|-------------|---------|
| Demand Environment | STRONG POSITIVE | GLP-1 TAM expanding $87B (2026) to $150-200B by 2032. Medicare $50 cap + Medicaid expansion adds 40M patients | 15 |
| Competitive Landscape | CAUTIONARY | Novo's 50% price cuts signal pricing war; LLY holds 58% total share but gap narrowing in some segments | 12 |
| Product/Moat Analysis | WIDE MOAT | Orforglipron no-dietary-restriction advantage vs oral semaglutide. Retatrutide 29% weight loss unprecedented. $50B manufacturing moat | 10 |
| Geopolitical/Regulatory | MIXED | Iran war adds macro uncertainty (+25bps WACC). FOMC hawkish (1 cut 2026). Medicare deal positive. IRA negotiation expanding | 8 |
| Historical Parallels | LOW APPLICABILITY | Gilead HCV (curative) pattern irrelevant; Vertex CF (chronic innovation) most analogous. Franchise extension probability: 65% | 6 |
| Novel/Contrarian Risks | CAUTIONARY | HSBC TAM correction thesis ($80-120B vs $150B consensus). Cash-pay channel sensitivity to Iran war economic impact. Muscle mass/rebound concerns persist | 8 |

**Total Sources Analyzed: 59**

### Notable Findings

The most material change since Feb 13 is Novo Nordisk's pricing strategy. The 50% list price cuts on Wegovy/Ozempic, $349/month cash-pay, and $199 intro offers signal that Novo has accepted market share loss and is competing on price to stabilize volumes. This pressures sector-wide GLP-1 margins by 2-3 years out. However, Lilly's superior clinical efficacy (tirzepatide > semaglutide on weight loss and A1C) should maintain pricing power at a premium — the question is how much premium.

HSBC's March 17 downgrade deserves serious analytical engagement. Their thesis that consensus TAM of ~$150B by 2030 is overstated ($80-120B more likely) has merit — adherence/persistence data shows 46-65% discontinuation within 1 year, which caps the "chronic use" assumption. Their $850 target uses 22x forward P/E, which would require meaningful growth deceleration. We incorporate this by weighting P/E compression (22x bear) at 15-20% probability.

The White House/Medicare deal is unambiguously positive but has a pricing offset. The $50/month Medicare cap expands volume access dramatically (40M+ patients), but Lilly is accepting lower per-unit economics on government programs in exchange for volume. Net effect is positive for revenue but slightly negative for blended margins.

## 8. Sector-Specific Analysis: Pipeline & Competitive Landscape

### Pipeline NPV Breakdown

| Asset | Status | Peak Sales ($B) | Probability | Risk-Adj NPV ($B) |
|-------|--------|-----------------|-------------|-------------------|
| Base Business (ex-tirzepatide) | Marketed | — | 95% | $258 |
| Tirzepatide Injectable | Approved | $58 | 90% | $355 |
| Orforglipron (oral GLP-1) | PDUFA Mar 28 | $18 | 88% | $133 |
| Retatrutide (triple agonist) | Phase 3 | $15 | 55% | $55 |
| Donanemab (Alzheimer's) | Approved | $4 | 85% | $26 |
| Label Expansions (HFpEF, MASH, CKD) | Phase 2-3 | $12 | 60% | $36 |
| Oncology + Other | Phase 1-2 | — | 25% | $10 |
| **Total Pipeline NPV** | | | | **$873B** |

Pipeline NPV per share: $873B / 945M = $924. Tirzepatide (injectable + oral) = 56% of total pipeline value.

### Patent Protection

| Patent Type | Expiration | Risk Level |
|-------------|------------|------------|
| Tirzepatide Composition of Matter | 2036 | Low (10 years) |
| Formulation Patents | 2039 | Low |
| Method-of-Treatment / Device | 2041 | Low |
| Patent Challenge Eligibility | May 2026 | Monitor |

### GLP-1 Competitive Landscape (Updated March 2026)

| Company | Drug | Status | Advantage | Market Share |
|---------|------|--------|-----------|-------------|
| Eli Lilly | Tirzepatide (injectable) | Approved | Superior efficacy, 70% new Rx | 58% total US |
| Eli Lilly | Orforglipron (oral) | PDUFA Mar 28 | No dietary restriction, convenience | Pending |
| Novo Nordisk | Semaglutide (injectable) | Approved | First mover, brand awareness | 42% total US |
| Novo Nordisk | Oral semaglutide | Approved | First oral GLP-1 | Early launch |
| Amgen | MariTide | Phase 3 | Monthly dosing | 2027-28E |
| Viking Therapeutics | VK2735 | Phase 2 | Oral, dual agonist | 2028E |
| Roche | CT-996 | Phase 2 | Oral, small molecule | 2028-29E |

### Key Change: Novo Nordisk Pricing War

Novo's pricing actions represent the most significant competitive development since our Feb 13 report:
- List price cuts: Up to 50% on Wegovy/Ozempic (effective Jan 2027)
- TrumpRx cash-pay: $349/month (from ~$1,350 list)
- Intro offers: $199 for first 2 months at low doses
- Medicare/Medicaid: $245 negotiated price

Lilly's response has been measured — maintaining premium pricing while expanding access through the White House Medicare $50/month cap deal. The key question is whether Novo's price cuts pull LLY into matching, or whether clinical superiority maintains the premium. Our base case assumes Lilly can maintain ~15-20% pricing premium over semaglutide, but this narrows from the current ~30% gap.

## 9. Catalysts & Risks

### Upcoming Catalysts

| Catalyst | Expected Date | Potential Impact | Direction | Probability |
|----------|--------------|------------------|-----------|-------------|
| Orforglipron FDA PDUFA | March 28, 2026 | $50-100/share | Positive | 88% |
| Medicare obesity coverage launch | April 1, 2026 | $20-40/share | Positive | 95% |
| Q1 2026 earnings | April 30, 2026 | $30-50/share swing | Mixed | — |
| Retatrutide Phase 3 data | H2 2026-27 | $50-80/share | Mixed | 55% |
| MASH indication filing | 2026-27 | $15-25/share | Positive | 60% |
| Iran war ceasefire/escalation | Ongoing | $20-40/share WACC impact | Mixed | — |

### Key Risks

| Risk | Category | Probability | Impact | Timeframe | Mitigant |
|------|----------|-------------|--------|-----------|----------|
| GLP-1 pricing war (Novo + competitors) | Competitive | 40% | Medium-High | 12-24mo | Clinical superiority, oral convenience moat |
| Orforglipron CRL or delay | Regulatory | 12% | High | Near | Strong Phase 3 data, priority voucher |
| Tirzepatide safety signal | Clinical | 10-12% | Very High | Any | Post-marketing surveillance, broad safety database |
| Multiple compression to 22x | Valuation | 25% | High | 6-12mo | Growth sustains premium if guidance met |
| Iran war economic spillover | Macro | 30% | Medium | 6-12mo | Healthcare defensive, essential spending |
| HSBC TAM correction materializes | Market | 20% | Medium | 12-36mo | Multiple indications expand beyond obesity |
| Cash-pay channel sensitivity | Demand | 25% | Medium | 6-12mo | Medicare/Medicaid offset cash-pay weakness |
| IRA negotiation + TrumpRx MFN | Regulatory | 70% | Medium | 2026-27 | Volume offsets price, label expansions |

### Contrarian Checklist

**What could make us wrong (Bull Direction):**
1. Orforglipron launch far exceeds HSBC's skepticism — $2B+ first-year sales (vs HSBC's $1.5B "unrealistic" call)
2. Medicare $50 cap triggers adoption cascade — obesity treatment becomes normalized medical care
3. Retatrutide Phase 3 shows 30%+ weight loss, establishing permanent next-gen dominance
4. GLP-1 TAM expands to $200B+ by 2030 as label expansions create multiple revenue streams beyond obesity/diabetes
5. Iran war de-escalation removes WACC premium and growth sentiment normalizes

**What could make us wrong (Bear Direction):**
1. HSBC thesis proves correct — TAM plateaus at $80-100B, adherence/persistence data disappoints
2. Novo's pricing war forces Lilly to cut Zepbound prices 20-30%, compressing margins
3. Orforglipron receives CRL — the oral convenience thesis collapses
4. Iran war escalates to Strait of Hormuz blockade, triggering recession and GLP-1 demand destruction in cash-pay channel
5. Muscle mass loss concerns escalate into class-wide regulatory review (FDA advisory committee)
6. Multiple compresses from 26x to 18-20x as market re-rates pharma growth sustainability

## 10. Position Recommendation

**Recommendation:** HOLD / ACCUMULATE on weakness

**Entry Range:** $780 — $900 (accumulate)
**Position Sizing:** 2-3% of portfolio (conviction level 2/3)
**Time Horizon:** 12-24 months
**Stop Loss:** $620 (severe bear — safety/regulatory shock)
**First Target:** $920 (base case fair value)
**Second Target:** $1,100 (moderate bull — pipeline execution)

**Timing Considerations:**
- The orforglipron PDUFA (March 28) is 4 days away — consider the binary risk. Approval is 88% probable but a CRL would send the stock to $780-820 temporarily.
- Q1 2026 earnings (April 30) will be the first quarter with Medicare obesity coverage and potentially orforglipron launch economics.
- Below $782 (lower band of 12-month FV range), upgrade to Accumulate. Below $700, upgrade to BUY.
- Above $1,058 (upper band), downgrade to Fairly Priced (High) and consider trimming.
- Iran war ceasefire would remove the +25bps WACC adjustment and push fair value up ~$40/share.

**vs Previous Report (Feb 13):**

| Metric | Feb 13 | Mar 24 | Change |
|--------|--------|--------|--------|
| Price | $1,038 | $903 | -13% |
| Rating | Fairly Priced (High) | Fairly Priced (Mid) | Upgrade |
| Conviction | 1 (Low) | 2 (Medium) | Upgrade |
| Fair Value (Base) | $908 | $920 | +1.3% |
| Upside to FV | -12.5% | +1.9% | Improved |
| Near-Term R/R | 0.67:1 | 1.14:1 | Improved |
| Action | HOLD, don't add | HOLD, accumulate on weakness | More constructive |

---

## Cross-Model Review

| Field | Value |
|-------|-------|
| Review Status | PENDING |
| Reviewer | GPT-5.4 via Codex MCP |
| Iterations | 0 |
| Review Date | 2026-03-24 |
| Key Corrections | Pending review |

---

*This report was generated by inv-AI's valuation framework using Claude (Opus 4.6) for analysis and GPT-5.4 for cross-model review. This is NOT financial advice. See [inv-ai.com/terms](https://www.inv-ai.com/terms) for full disclaimer.*

*AI-readable version. For the styled human-readable report, see [LLY.html](/reports/LLY.html).*